Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | SVP, Chief Scientific Officer | March 10, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date March 10, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,700 |
Reported balance
After 2022-03-10 transaction · row 1
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 24,700 · Balance 43,700 F1: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2032-03-10 | Direct | 100,000 |
Reported balance
After 2022-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-10 · Grant · Acquired 100,000 · Balance 100,000 F2: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033389 · tm229119-1_4seq1.xml · derivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 24,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033389 · tm229119-1_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,700 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · derivative · entry 3 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,587 Underlying: Common Stock · 50,000 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 50,000 | $4.89 | $244,500.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · nonDerivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.05 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 50,000 | $0.92 | $46,000.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · derivative · entry 3 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,587 Underlying: Common Stock · 25,000 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 25,000 | $4.97 | $124,250.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · nonDerivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.57 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 25,000 | $0.92 | $23,000.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:08 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 82,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006732 · form4.xml · derivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2031-02-25 F2 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:08 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006732 · form4.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 6,333 shares on February 25, 2022, (ii) 6,333 shares on February 25, 2023 and (iii) 6,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 31,600 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001104659-20-038879 · a4.xml · derivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,600 Underlying: Common Stock · 31,600 shares Expires 2030-03-24 F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:19 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 77,630 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-19-018075 · form4.xml · derivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,630 Underlying: Common Stock · 77,630 shares Expires 2029-10-02 F1 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.